Targeting the insulin-like growth factor pathway in estrogen receptor-positive breast cancer: A bumpy start with an uncertain future

Journal of Clinical Oncology

Volumn 29, Issue 29, 2011, Pages 3846-3848

  Dickler, Maura N ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ANASTROZOLE; ANTINEOPLASTIC AGENT; BMS 754807; C PEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GANITUMAB; INSULIN; INSULIN RECEPTOR; LAPATINIB; LETROZOLE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; OCTREOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CELL PROLIFERATION; CHOLECYSTECTOMY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG TOLERABILITY; EDITORIAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GALLBLADDER DISEASE; GASTROINTESTINAL PAIN; GLUCONEOGENESIS; HORMONE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INHIBITION KINETICS; INTRACELLULAR SIGNALING; LIGAND BINDING; METASTASIS; MOLECULARLY TARGETED THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR UPREGULATION; TREATMENT RESPONSE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; TAMOXIFEN;

EID: 80053956239     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.6393     Document Type: Editorial

References (25)

1. Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002 (Pubitemid 34694019)
2. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005
3. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004 (Pubitemid 38298988)
4. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003 (Pubitemid 37362955)
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
6. Massarweh S, Schiff R: Unraveling the mechanisms of endocrine resistance in breast cancer: New therapeutic opportunities. Clin Cancer Res 13:1950-1954, 2007
7. Kaufman B, Mackey JR, Clemens MR, et al: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol 27:5529-5537, 2009
8. Johnston S, Pippen J Jr, Pivot X, et al: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538-5546, 2009
9. Fagan DH, Yee D: Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 13:423-429, 2008
10. Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928, 2008
11. Lisztwan J, Pornon A, Chen B, et al: The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Res 10:R56, 2008
12. Goodwin PJ, Ennis M, Pritchard KI, et al: Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. J Clin Oncol 20:42-51, 2002 (Pubitemid 34032594)
13. Irwin ML, Duggan C, Wang CY, et al: Fasting C-peptide levels and death resulting from all causes and breast cancer: The Health, Eating, Activity, and Lifestyle study. J Clin Oncol 29:47-53, 2010
14. Pritchard KI, Shepherd LE, Chapman J-AW, et al: Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA. 14. J Clin Oncol 29:3869-3876, 2011
15. Bornschein J, Drozdov I, Malfertheiner P: Octreotide LAR: Safety and tolerability issues. Expert Opin Drug Saf 8:755-768, 2009
16. Lamberts SW, van der Lely AJ, de Herder WW, et al: Octreotide. N Engl J Med 334:246-254, 1996 (Pubitemid 26030676)
17. Kaufman PA, Bourgeois H, Kennecke H, et al: A randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane or fulvestrant in postmenopausal women with hormone-receptor positive metastatic or locally advanced breast cancer. Cancer Res 70:76s, 2010 (suppl)
18. Yao S, Sucheston LE, Millen AE, et al: Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: A case-control and a case-series study. PLoS One 6:e17251, 2011
19. Chlebowski RT, Johnson KC, Kooperberg C, et al: Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 100:1581-1591, 2008
20. Manson JE, Mayne ST, Clinton SK: Vitamin D and prevention of cancer: Ready for prime time? N Engl J Med 364:1385-1387, 2011
21. Goodwin PJ, Ennis M, Pritchard KI, et al: Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 27:3757-3763, 2009
22. Pollak M: Metformin and other biguanides in oncology: Advancing the research agenda. Cancer Prev Res (Phila) 3:1060-1065, 2010
23. Evans JM, Donnelly LA, Emslie-Smith AM, et al: Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304-1305, 2005 (Pubitemid 40813563)
24. Jiralerspong S, Palla SL, Giordano SH, et al: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297-3302, 2009
25. Goodwin PJ, Ligibel JA, Stambolic V: Metformin in breast cancer: Time for action. J Clin Oncol 27:3271-3273, 2009